Crawford Lake Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Crawford Lake Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-105,099	Closed	-$12.5M	–	87
2018 Q1	$12.5M	Sell	105,099 -11,029	-9%	-$1.42M	2.67%	13
2017 Q4	$14.8M	Buy	116,128 +56,002	+93%	+$7.04M	3.48%	9
2017 Q3	$7.06M	Buy	+60,126	New	+$5.13M	2.53%	14

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Crawford Lake Capital Management's ALNY Position: Q2 2018 in Review

Crawford Lake Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2018, closing a stake of 105,099 shares — an estimated $12.5M sold.

Crawford Lake Capital Management first reported a position in ALNY in Q3 2017 and held it in 3 quarters. The position peaked at $14.8M in Q4 2017. 309 funds tracked by Wall St. Rank hold ALNY as of Q2 2018.

Crawford Lake Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Crawford Lake Capital Management sold 105,099 Alnylam Pharmaceuticals shares in Q2 2018, an estimated $12.5M.
Crawford Lake Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2017 and held it in 3 quarters.
Crawford Lake Capital Management's Alnylam Pharmaceuticals position peaked at $14.8M in Q4 2017.
309 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2018.

Based on Crawford Lake Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.